Merkel cell carcinoma: what is next?
Thomas S. Bander, MD 1 and Kelly L. Harms, MD, PhD 2 M erkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine carcinoma which was first described in 1972. MCC typically presents as a red to violaceous papule or nodule on sun-exposed skin of older patients or those who are immunosuppressed. The primary lesion often grows rapidly over 2-3 months and has a higher risk of metastasis to nodal basins and distant sites than melanoma. Due to the rarity of the disease, its etiology was unclear until a pivotal discovery of viral sequences in tumor samples. In 2008, this polyomavirus was identified and named Merkel cell polyomavirus (MCPyV). 1 Since then, research into disease pathogenesis, prognostic markers, and treatment paradigms has flourished. 2 MCC is currently thought to arise from MCPyV-or ultraviolet (UV)-mediated DNA mutations. 1, 3, 4, 5 MCPyV is a ubiquitous virus, and most people are exposed in childhood. Tumorigenesis via MCPyV is thought to occur in association with two rare events: integration of viral genome into host genome and truncation of the viral large T antigen gene product which abrogates viral replication. It is estimated that up to 80% of MCC are associated with MCPyV; however, the percentage varies and has been reported to be lower in Australia likely due to high UV index and more prevalent UV-associated pathogenesis. 6 To date, studies have been mixed on the prognosis of viral positivity, but the largest study suggests it is a positive prognostic factor. 7 Historically, management of stage IV disease involved cytotoxic chemotherapy, and responses were not durable. In 2016, it was shown that metastatic MCC has a durable response to immune checkpoint inhibition, transforming the medical management of advanced disease. 8, 9, 10 Importantly, the prognosis of MCC is now improved and historical data will be just that-history. Future research using large national databases may help compare diagnosis and management before and after the availability of immunotherapy, but it will take time to collect this new data. Now that we have successful treatment options for patients with stage IV disease, we must continue to refine our treatment paradigm. Many questions remain. How do we minimize side effects while maintaining therapeutic benefit? Will new prognostic factors demonstrate enough significance to include in staging systems? With improved response to therapy, we may turn our attention to factors that influence recurrence. What are the biologic predictors of recurrence? Will adjuvant immunotherapy prevent recurrence? What tumor burden is necessary for adjuvant immunotherapy to be effective? What is the role of neoadjuvant immunotherapy? Carefully designed clinical trials and other studies will be necessary to address unmet needs in therapy and further our understanding of the natural history of this disease. 
